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Background: Chronic inflammation may play a role in colorectal cancer (CRC) pathogenesis. The relationship between soluble
tumour necrosis factor receptor type II (sTNF-RII) and survival among CRC patients is not well defined.
Methods: We prospectively evaluated the association between pre-diagnosis plasma levels of sTNF-RII and mortality in 544 CRC
patients from the Nurses’ Health Study and Health Professionals Follow-Up Study diagnosed from 1990 to 2010. Primary and
secondary end points were overall and CRC-specific mortality, respectively. Cox proportional hazards models were used to
calculate multivariate hazard ratios for mortality.
Results: Higher sTNF-RII levels were significantly associated with increased overall mortality (multivariate HR¼ 1.48, 95% CI 1.02–
2.16, P-trend¼ 0.006), but not with CRC-specific mortality (HR¼ 1.23, 95% CI 0.72–2.08, P-trend¼ 0.34). In subgroup analyses,
among regular aspirin users, those with higher sTNF-RII levels had an adjusted HR of 0.52 (95% CI 0.20–1.33) for overall mortality
compared with those with lower sTNF-RII levels, whereas among nonregular aspirin users the adjusted HR was 2.26 (95% CI 1.23–
4.01, P for interaction¼ 0.53).
Conclusions: Among CRC patients, higher sTNF-RII levels are associated with a significant increase in overall mortality, but not
CRC-specific mortality. The role of inflammation and anti-inflammatory medications in survival of CRC patients warrants further
exploration.
Chronic inflammation may play a role in the development and
progression of colorectal cancer (CRC) (Bernstein et al, 2001; Kant
and Hull, 2011; Song et al, 2013). Soluble tumour necrosis factor
receptor type II (sTNF-RII; (HUGO Gene Nomenclature Com-
mittee (HGNC) ID TNFRSF1B) is the plasma form of the 75 kD
cell surface receptor for the pro-inflammatory cytokine tumour
necrosis factor-a (TNF-a) (Spoettl et al, 2007; Faustman and Davis,
2010). In CRC cells, TNF-a activates various inflammatory
pathways and induces expression of cyclooxygenase-2 (COX-2),
prostaglandin synthesis, increased tumour growth, and angiogen-
esis (Popivanova et al, 2008; Hamilton et al, 2011; Setia et al, 2013;
Zhu et al, 2013). The TNF-a signalling is also associated with
decreased apoptosis and chemotherapy resistance in metastatic
CRC (Matsuyama et al, 2006).
Prospective observational studies have shown an association
between sTNF-RII and increased risk of incident CRC in women
(Chan et al, 2011). Multiple large randomised clinical trials have
shown that inhibition of inflammation with medications such as
*Correspondence: K Ng; E-mail: kimmie_ng@dfci.harvard.edu
8These two authors contributed equally to this work.
Revised 3 March 2016; accepted 8 March 2016; published online 31 March 2016
& 2016 Cancer Research UK. All rights reserved 0007 – 0920/16
FULL PAPER
Keywords: soluble tumour necrosis factor receptor type II; colorectal cancer; aspirin; NSAIDs
British Journal of Cancer (2016) 114, 995–1002 | doi: 10.1038/bjc.2016.85
www.bjcancer.com |DOI:10.1038/bjc.2016.85 995
aspirin and COX-2 (PTGS2) inhibitors can effectively prevent
formation of colorectal adenomas in patients with a history of
polyps or CRC (Steinbach et al, 2000; Sandler et al, 2003; Arber
et al, 2006; Bertagnolli et al, 2006). Moreover, regular aspirin use
has also been associated with improved survival in CRC patients
(Chan et al, 2009). In contrast, the role of sTNF-RII in patients
with established CRC is less clear. We therefore conducted a
prospective study to investigate the association between levels of
sTNF-RII and mortality in CRC patients from two large, well-
established cohorts with over 20 years of follow-up data.
MATERIALS AND METHODS
Study population. Participants were drawn from the Nurses’
Health Study (NHS) and Health Professionals Follow-Up Study
(HPFS). The NHS cohort was established in 1976 when 121 700 US
female registered nurses aged 30–55 years completed a mailed
questionnaire regarding their health history (Belanger et al, 1978;
Colditz et al, 1997). Every 2 years, follow-up questionnaires were
mailed to participants to update information on medical history,
medication use, lifestyle factors, and chronic diseases. Between
May 1989 and September 1990, blood samples were collected from
32 826 participants. NHS cohort follow-up is B96%.
The HPFS cohort was established in 1986 when 51 529 male
medical providers aged 45 to 70 years completed a mailed
questionnaire regarding their health history (Rimm et al, 1991;
Giovannucci et al, 1994). Every 2 years, follow-up questionnaires
were mailed to participants to update information on medical
history and medication use. Between 1993 and 1995, blood samples
were also collected from 18 225 participants. HPFS cohort follow-
up is B95%.
Inclusion criteria. Participants were included in this analysis if
they provided a blood sample and had a pathologically confirmed
diagnosis of CRC between the date of blood sampling and June
2010 for NHS and January 2010 for HPFS. To identify CRC cases,
participants were asked on each follow-up questionnaire whether
they had a diagnosis of CRC during the previous 2 years. When a
diagnosis of CRC was reported by a participant or next of kin (if
the patient was deceased at the time of contact), permission was
obtained to retrieve hospital records and pathology reports.
Blinded study physicians reviewed these records and recorded
information on stage and important tumour characteristics. For
nonrespondents, the National Death Index was used to confirm
death and ascertain whether CRC contributed to death or was a
secondary diagnosis. It is estimated that 96% of CRC cases were
identified using these methods (Giovannucci et al, 2006).
Exclusion criteria. Patients were excluded from this analysis if
they reported a diagnosis of cancer (other than non-melanoma
skin cancer) or inflammatory bowel disease (IBD) before CRC
diagnosis. To minimise any bias in the plasma levels of sTNF-RII
associated with occult cancer, patients diagnosed with CRC within
2 years of blood collection were excluded. Based on these criteria,
319 women from the NHS cohort and 225 men from the HPFS
cohort were eligible for analysis, for a total of 544 participants. All
patients provided informed consent for use of their clinical data
and biospecimens in the study that was approved by the
institutional review board at Brigham and Women’s Hospital
and Harvard School of Public Health.
sTNF-RII measurement. Blood samples were collected in tubes
with heparin and sent to our laboratory by overnight courier in
chilled containers. Blood samples were centrifuged, aliquoted, and
stored in liquid nitrogen freezers at  160 1C. Levels of sTNF-RII
were measured in a single run in a core laboratory using enzyme-
linked immunosorbent assay (R&D Assays, Minneapolis, MN, USA)
by blinded laboratory personnel. Blinded quality control samples
were interspersed alongside test samples, and the intra-assay
coefficient of variation for sTNF-RII was 6.7% (Chan et al, 2011).
The sTNF-RII is an accepted surrogate measurement for TNF-a
because of its increased measurement stability in frozen blood
samples, less diurnal variation, and its role in TNF-a signalling
(Diez-Ruiz et al, 1995; Liu et al, 2007). Whereas plasma TNF-a
levels tend to fluctuate, sTNF-RII levels in humans remain stable
over long periods of time (Epstein et al, 2013). The stability of
sTNF-RII measurements from blood samples stored for 24 h before
processing compared with measurements obtained from samples
frozen immediately after collection has been previously confirmed,
with an assay intra-class correlation of 0.91 (Chan et al, 2011; Song
et al, 2013).
Outcome assessment. Participants were followed from the time of
diagnosis until death or June 2012 (NHS) or January 2013 (HPFS),
whichever came first. Confirmation of death included reporting by
family or postal authorities. Names of persistent nonresponders
were searched in the National Death Index. Cause of death was
assigned by blinded study physicians. More than 98% of deaths
have been identified by these methods (Stampfer et al, 1984;
Giovannucci et al, 2006). Overall mortality was defined as duration
of time from CRC diagnosis to death from any cause. The CRC-
specific mortality was defined as duration of time from diagnosis to
death related to CRC. Non-CRC-specific mortality was defined as
duration of time from diagnosis to death related to causes other
than CRC. Patients not experiencing outcomes of interest were
censored either at the time of death or at the end of the observation
period defined above, if still alive.
Covariates. Data on clinically relevant covariates were extracted
from questionnaires and medical records, including age at blood
draw, sex, race, tumour stage at diagnosis, primary tumour site,
histologic grade of differentiation, year of diagnosis (surrogate for
treatment received), time between blood draw and CRC diagnosis,
body mass index (BMI) at blood draw, physical activity at blood
draw, and use of aspirin or non-steroidal anti-inflammatory drug
(NSAID) at blood draw and post diagnosis. Post-diagnosis
covariates were taken from the first questionnaire between years
1 and 4 after diagnosis to avoid confounding by the immediate
postoperative period or recent chemotherapy. Regular aspirin or
NSAID users were defined as those using X2 tablets of regular-
strength aspirin or NSAID per week. Nonregular users were
defined as patients who either did not use those medications or
who used o2 tablets per week.
Statistical analysis. We controlled for batch-to-batch variability
using the method described by Rosner et al (2008). Quartiles of
sTNF-RII were determined separately within each cohort. Hazard
ratios (HRs) were calculated separately for HPFS and NHS and
subsequently pooled for the primary analysis using a meta-analysis
with a fixed effects model. Heterogeneity across cohorts was tested
using the Q-statistic (DerSimonian and Laird, 1986). Overall
mortality was assessed according to quartile of sTNF-RII using
Kaplan–Meier curves and the log-rank test. Cox proportional
hazards models were used to calculate HRs of death from all causes
or death because of CRC. Models were stratified by stage and grade
at diagnosis and adjusted for the potential confounding factors
listed above, with the lowest quartile of sTNF-RII as the referent.
The two-tailed P-value for the linear trend test across categories
was calculated using sTNF-RII as a continuous variable in the final
multivariate model (Allison, 1995).
Analyses of the relationship between sTNF-RII and mortality
were also conducted within subgroups of prespecified covariates
using the same model as detailed above. For continuous variables
(i.e., age and physical activity), cut-points were determined by the
median value. Patients with missing data for the subgroup of
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Table 1. Baseline characteristics of study cohort according to quartile of sTNF-RII (n¼544)
Baseline characteristics Quartile 1 (n¼135) Quartile 2 (n¼136) Quartile 3 (n¼137) Quartile 4 (n¼136)
Mean age at blood draw, years (s.e.) 58.5 (0.70) 60.9 (0.64) 62.5 (0.63) 64.3 (0.68)
Sex, no. (%)
Male 56 (41) 56 (41) 57 (42) 56 (41)
Female 79 (59) 80 (59) 80 (58) 80 (59)
Stage, no. (%)
I 44 (33) 36 (26) 36 (26) 31 (23)
II 32 (24) 42 (31) 26 (19) 28 (21)
III 26 (19) 21 (15) 31 (23) 28 (21)
IV 17 (13) 16 (12) 18 (13) 24 (18)
Unknown/missing 16 (12) 21 (15) 26 (19) 25 (18)
Race, no. (%)
White 128 (95) 134 (99) 131 (96) 135 (99)
African American 3 (2) 1 (1) 0 (0) 0 (0)
Other 1 (1) 0 (0) 0 (0) 0 (0)
Missing 3 (2) 1 (1) 6 (4) 1 (1)
Tumour location, no. (%)
Proximal colon 41 (30) 67 (49) 59 (43) 65 (48)
Distal colon 49 (36) 35 (26) 37 (27) 31 (23)
Rectum 40 (30) 21 (15) 27 (20) 24 (18)
Unknown 5 (4) 13 (10) 14 (10) 16 (12)
Family history of colorectal cancer, no. (%)
Yes 44 (33) 44(32) 42 (31) 41 (30)
No 91 (67) 92 (68) 95 (69) 95 (70)
Mean time between blood draw and
diagnosis, years (s.e.)
8.4 (0.3) 9.8 (0.4) 9.2 (0.4) 8.6 (0.4)
Grade of differentiation, no. (%)
Well differentiated 22 (16) 12 (9) 11 (8) 9 (7)
Moderately differentiated 74 (55) 79 (58) 80 (58) 73 (54)
Poorly differentiated or undifferentiated 22 (16) 18 (13) 17 (12) 18 (13)
Unknown 17 (13) 27 (20) 29 (21) 36 (26)
Year of diagnosis, no. (%)
1990–2000 83 (61) 61 (45) 64 (47) 78 (57)
2001–2010 52 (39) 75 (55) 73 (53) 58 (43)
Tobacco use at blood draw, no. (%)
Never smoker 48 (36) 58 (43) 63 (46) 63 (46)
Past smoker 77 (57) 66 (49) 61 (45) 55 (40)
Current smoker 10 (7) 11 (8) 12 (9) 18 (13)
Missing/unknown 0 (0) 1 (1) 1 (1) 0 (0)
Regular aspirin usea
At blood draw, no. (%)
Yes 30 (22) 31 (23) 32 (23) 31 (23)
No 79 (59) 70 (51) 67 (49) 58 (43)
Missing/unknown 26 (19) 35 (26) 38 (28) 47 (35)
1–4 Years after diagnosis, no. (%)
Yes 39 (29) 39 (29) 53 (39) 52 (38)
No 94 (70) 94 (69) 80 (58) 81 (60)
Missing/unknown 2 (1) 3 (2) 4 (3) 3 (2)
Regular anti-inflammatory medication useb
At blood draw, no. (%)
Yes 16 (12) 17 (13) 17 (12) 19 (14)
No 106 (79) 108 (79) 107 (78) 103 (76)
Missing/unknown 13 (10) 11 (8) 13 (9) 14 (10)
1–4 Years after diagnosis, no. (%)
Yes 13 (10) 18 (13) 20 (15) 13 (10)
No 103 (76) 100 (74) 95 (69) 97 (71)
Missing/unknown 19 (14) 18 (13) 22 (16) 26 (19)
BMI, kgm2
At blood draw, no. (%)
Normal weight (o25) 41 (30) 30 (22) 26 (19) 35 (26)
Overweight (25–29.9) 69 (51) 73 (54) 75 (55) 69 (51)
Obese (X30) 25 (19) 33 (24) 36 (26) 32 (24)
At diagnosis, no. (%)
Normal weight (o25) 31 (23) 30 (22) 32 (23) 35 (26)
Overweight (25–29.9) 66 (49) 62 (46) 55 (40) 59 (43)
Obese (X30) 38 (28) 44 (32) 50 (37) 42 (31)
Median level of physical activity, MET-h per week (IQR)
1–4 Years after diagnosis 12.7 (6.0–27.1) 8.5 (5.4–21.8) 11.1 (6.9–17.7) 8.5 (4.0–16.5)
At blood draw 15.4 (6.0–29.0) 13.5 (4.0–33.9) 13.9 (5.9–31.1) 11.8 (3.5–27.0)
Abbreviations: BMI¼body mass index; IQR¼ interquartile range; MET¼metabolic equivalent task; sTNF-RII¼ soluble tumour necrosis factor receptor type II. Quartile sTNF-RII ranges
(pgml 1): quartile 1: 1304–2361; quartile 2: 2346–2767; quartile 3: 2755–3297; and quartile 4: 3186–9572.
aA standard tablet contains 325mg of aspirin, and regular aspirin use is defined as taking at least two tablets of aspirin per week.
bRegular anti-inflammatory drug users were defined as those who used at least two tablets of a non-steroidal anti-inflammatory drug (NSAID) per week or any use of a cyclooxygenase-2 (COX-2) inhibitor.
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interest were excluded from the analysis. Tests of interaction
between sTNF-RII and potential effect modifiers were assessed by
Wald’s test of cross-product terms created by multiplying the
covariate of interest with sTNF-RII as a continuous variable. All
analyses used SAS software, version 9.3 (SAS Institute Inc., Cary,
NC, USA).
RESULTS
Among the eligible 544 patients, there were 299 deaths, with 163
deaths (55%) because of CRC. Non-CRC causes of death included
cardiovascular disease (n¼ 30, 22%), other malignancies (n¼ 23,
17%), neurologic disorders (n¼ 24, 18%), pulmonary disorders
(n¼ 10, 7%), miscellaneous causes (n¼ 26, 19%), and unknown
reasons, typically because of the inability to confidently assign a
single cause (n¼ 23, 17%).
The median duration of follow-up of patients still alive at the end of
the study was 11.5 years (range 3.9–20.5 years). The median follow-up
of patients who died of any cause was 3.6 years (range 0–21.2 years).
The median follow-up of those patients who died of CRC was 1.5 years
(range 0–16.9 years). The sTNF-RII levels were measured at a median
of 8.7 years before CRC diagnosis (range 2–16.9 years).
Baseline characteristics according to quartile of plasma sTNF-
RII are shown in Table 1. Most characteristics did not differ
significantly across quartiles. Patients with higher levels of sTNF-
RII appeared to be older, have stage IV disease at diagnosis, have
proximal rather than distal colon or rectal tumours, be diagnosed
earlier than 2001, and have a higher BMI at blood draw. There was
no significant difference in the mean time between blood draw and
diagnosis of CRC between sTNF-RII quartiles.
Kaplan–Meier curves for overall survival (Figure 1) and CRC-
specific survival (Figure 2) by quartile of sTNF-RII are shown. Log-
rank testing demonstrated a statistically significant difference in
overall survival (Po0.0001) and CRC-specific survival (P¼ 0.05)
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Figure 2. Colorectal cancer-specific survival by quartile of sTNF-RII.
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Figure 1. Overall survival by quartile of sTNF-RII.
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between quartiles of sTNF-RII. The association between pre-
diagnosis sTNF-RII levels and overall survival in CRC patients
remained significant after adjustment for potential confounders
(Table 2). Patients with higher sTNF-RII plasma levels had a HR
for overall mortality of 1.48 (95% CI 1.02–2.16, P-trend¼ 0.006)
compared with the lowest levels. Excluding stage IV patients at
diagnosis, who typically have higher levels of inflammation and
worse prognosis, did not appreciably alter the results (HR¼ 1.69,
95% CI 1.05–2.72). In contrast, after multivariate adjustment,
increasing levels of sTNF-RII were not significantly associated with
increased CRC-related mortality (HR¼ 1.23, 95% CI 0.72–2.08,
P¼ 0.34). We also found a statistically significant difference in non-
CRC-specific survival (Po0.0001) between sTNF-RII quartiles
(Kaplan–Meier curve data not shown). The significantly increased
risk of non-CRC-related mortality among patients with higher sTNF-
RII levels persisted after multivariate adjustment (HR¼ 1.91, 95% CI
1.09–3.37, P-trend¼ 0.002; Table 2). Of note, there was no significant
association between sTNF-RII and cardiovascular mortality specifi-
cally (HR¼ 1.84, 95% CI 0.58–5.81, P-trend¼ 0.15). When exam-
ined separately by cohort, there was no significant difference in
association between sTNF-RII and overall (P-heterogeneity¼ 0.86),
CRC-related (P-heterogeneity¼ 0.19), or non-CRC-related mortality
(P-heterogeneity¼ 0.63; Supplementary Table 1).
To address the possibility of competing risks of non-CRC-
related death, we performed a competing risk analysis (Lunn and
McNeil, 1995) and obtained similar results. Compared with
patients with lowest sTNF-RII, patients with highest levels were
not at statistically higher risk of CRC-related death (HR¼ 1.29,
95% CI 0.78–2.12), but were at increased risk of non-CRC death
(HR¼ 2.13, 95% CI 1.22–3.70). We performed subgroup analyses
of the association of sTNF-RII with overall mortality (Figure 3).
For most subgroups, the increased risk of all-cause mortality
associated with higher levels of sTNF-RII was preserved. Interest-
ingly, however, among patients who reported regular aspirin use
after diagnosis, higher sTNF-RII levels were not associated with an
increased risk of death (multivariate HR¼ 0.52, 95% CI 0.20–1.33).
In contrast, nonregular aspirin users in the highest quartile of
sTNF-RII showed a multivariate HR of 2.26 (95% CI 1.23–4.04)
compared with the lowest quartile (P for interaction¼ 0.53).
DISCUSSION
We found that higher pre-diagnosis sTNF-RII levels were
associated with an B48% increase in overall mortality compared
with lower sTNF-RII levels after adjustment for potential
confounding factors. Among regular users of aspirin after
diagnosis, however, increasing levels of sTNF-RII were not
associated with worse mortality in exploratory subgroup analyses,
though the P for interaction was not significant. Interestingly, we
did not see a statistically significant association between higher
sTNF-RII levels and CRC-specific mortality after multivariate
adjustment.
Although decreased power and the strong association between
sTNF-RII and non-CRC-related death are potential explanations
for the nonsignificant relationship between sTNF-RII and CRC-
specific mortality, it is also plausible that higher circulating sTNF-
RII adversely affects mortality via non-CRC-related pathways.
Non-colorectal causes of death in our cohort included cardiovas-
cular disease, other malignancies, neurologic disorders, and
pulmonary disease, all of which are characterised by chronic
inflammation. Moreover, several studies have demonstrated that
elevated plasma sTNF-RII is associated with increased mortality in
these diseases (Dobrzycka et al, 2009; Heemann et al, 2012;
Schnabel et al, 2013). For example, previous analyses have clearly
shown associations between sTNF-RII and cardiovascular disease,
such as risk of incident coronary heart disease in healthy women
(Pai et al, 2004), myocardial infarction in diabetic women in the
NHS cohort (Shai et al, 2005), and cardiovascular mortality in the
Framingham Heart Study (Schnabel et al, 2013). Consistent with
this, we demonstrated a two-fold increase in risk of non-CRC-
related mortality among CRC patients with elevated sTNF-RII
levels. We also found that higher sTNF-RII levels were associated
with increased cardiovascular mortality among CRC patients, but
this was not statistically significant because of the small number of
patients in our study who died of cardiovascular disease (n¼ 30).
These results suggest that comorbid inflammatory conditions may
carry important prognostic implications for CRC patients (De
Marco et al, 2000), a finding that is increasingly relevant in the
Table 2. Age-adjusted and multivariate hazard ratios for mortality by quartile of sTNF-RII (n¼544)
Quartile 1 Quartile 2 Quartile 3 Quartile 4
Range of sTNF-RII (pgml1)
NHS cohort (N¼ 319) (1459–2344) (2346–2752) (2755–3185) (3186–9572)
HPFS cohort (N¼225) (1304–2361) (2361–2767) (2771–3297) (3328–5512)
Overall mortality
No. Events HR (95% CI) No. Events HR (95% CI) No. Events HR (95% CI) No. Events HR (95% CI) P-trenda
Age adjustedb 135 58 Referent 136 62 1.09 (0.76–1.56) 137 76 1.28 (0.90–1.81) 136 103 1.78 (1.27–2.48) 0.0005
Multivariatec 135 58 Referent 136 62 0.93 (0.63–1.38) 137 76 1.17 (0.80–1.70) 136 103 1.48 (1.02–2.16) 0.006
Colorectal cancer mortality
No. Events HR (95% CI) No. Events HR (95% CI) No. Events HR (95% CI) No. Events HR (95% CI) P-trend
Age adjustedb 135 34 Referent 136 35 1.04 (0.64–1.70) 137 44 1.25 (0.77–2.01) 136 50 1.49 (0.95–2.35) 0.12
Multivariatec 135 34 Referent 136 35 1.05 (0.62–1.78) 137 44 1.25 (0.75–2.10) 136 50 1.23 (0.72–2.08) 0.34
Non-colorectal cancer-specific mortality
No. Events HR (95% CI) No. Events HR (95% CI) No. Events HR (95% CI) No. Events HR (95% CI) P-trenda
Age adjustedb 135 24 Referent 136 27 1.12 (0.63–2.00) 137 32 1.29 (0.75–2.21) 136 53 2.18 (1.31–3.63) 0.0002
Multivariatec 135 24 Referent 136 27 0.84 (0.45–1.55) 137 32 1.00 (0.55–1.83) 136 53 1.91 (1.09–3.37) 0.002
Abbreviations: 95% CI¼ 95% confidence interval; HPFS¼Health Professionals Follow-Up Study; HR¼ hazard ratio; NHS¼Nurses’ Health Study; sTNF-RII¼ soluble tumour necrosis factor
receptor type II.
aP-trend calculated by using sTNF-RII as a continuous variable in the Cox model.
bHRs, 95% CIs, and P-values are adjusted for age at blood draw (years).
cMultivariate HRs, 95% CIs, and P-values are calculated using a meta-analysis (fixed effects model) by cohort, stratified by stage (I–III, IV, or unknown) and grade (well or moderately
differentiated, poorly differentiated, or unknown), and adjusted for age at blood draw (in years as a continuous variable), location of primary tumour (proximal, distal, rectum, or unknown), year
of diagnosis (as a continuous variable), time between blood draw and diagnosis (in years as a continuous variable), body mass index at blood draw (in kgm 2 as a continuous variable), physical
activity at blood draw (in metabolic equivalent-h per week as a continuous variable), and regular aspirin or anti-inflammatory use at blood draw.
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context of the longer life expectancy of CRC patients in recent
years.
Interestingly, our study found that higher sTNF-RII levels were
not associated with worse outcome among patients who reported
regular aspirin use, although the P-value for interaction between
sTNF-RII and aspirin was not significant, possibly because of
reduced power in exploratory subgroup analyses. Ample clinical
data (Algra and Rothwell, 2012) suggest that initiation of aspirin
after CRC diagnosis may be beneficial in reducing mortality,
particularly among older patients (Lai and Liao, 2013) and COX-2-
overexpressing (Chan et al, 2009) or PIK3CA-mutated tumours
(Liao et al, 2012; Langley and Rothwell, 2013). Moreover,
treatment with COX inhibitors leads to inhibition of TNF-a-
induced COX-2 expression and decreased proliferation of CRC
cells (Ricchi et al, 1997; Paik et al, 2000), thus lending biologic
plausibility to our findings. Currently, a large, randomised
Intergroup study, CALGB/Alliance 80702, is testing the efficacy
of celecoxib, a selective COX-2 inhibitor, for preventing disease
recurrence in stage III colon cancer patients, and future studies
should investigate the impact of these medications on TNF-a
signalling and prognosis.
The strengths of our study include its prospective design, and
use of two established cohorts with high rates of long-term follow-
up for measurement of confounders and mortality end points.
Moreover, NHS and HPFS participants are motivated medical
professionals who provide accurate information about potential
confounders and outcomes.
A potential study limitation is that only one measurement of
sTNF-RII was drawn before diagnosis; however, previous studies
have demonstrated that sTNF-RII levels stay fairly constant over
time (Epstein et al, 2013). Higher sTNF-RII levels may also be a
consequence of cancer, rather than a factor in the causative
Female
Age at diagnosis >71
Age at diagnosis 71
Male
Diagnosed before
2000
Diagnosed after 2000
Colon
Rectum
BMI normal
BMI overweight/obese
ASA use after
diagnosis 0.53
0.50
0.81
0.67
0.22
0.16
P for interaction
0.91
0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
No ASA use after
diagnosis
Physical activity < 9.6
MET-h per week
Physical activity > 9.6
MET-h per week
Figure 3. Relationship between sTNF-RII and overall mortality in prespecified patient subgroups. Multivariate hazard ratios (HRs) and 95%
confidence intervals (CIs) for overall mortality across subgroups of various factors, comparing CRC patients in the highest quartile of plasma sTNF-
RII levels with patients in the lowest sTNF-RII quartile. Subgroups include age at diagnosis (less than or equal to cohort median diagnosis age of 71
years, greater than cohort median diagnosis age), sex (male, female), year of diagnosis (before and including the year 2000, after the year 2000),
tumour location at diagnosis (colon, rectum), BMI (kgm 2) at diagnosis (normal weight, overweight, or obese), regular aspirin (ASA) use 1–4 years
after diagnosis (yes, no), and physical activity 1–4 years after diagnosis (less than or equal to cohort median physical activity of 9.6 metabolic
equivalent task (MET)-h per week, greater than median physical activity).
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pathway, or reflect other poor prognostic factors. However, we
adjusted our analysis for potential risk factors for CRC mortality,
and attempted to control for reverse causation by excluding
patients diagnosed with CRC within 2 years of blood draw.
Moreover, excluding patients with stage IV disease at diagnosis
(who often have the highest sTNF-RII levels and mortality rates)
from the analysis did not significantly alter our results. Although
NHS and HPFS cohort questionnaire data are extensive, informa-
tion about treatment is limited, and hence we adjusted the analysis
for year of diagnosis as a surrogate for treatment. Another
limitation is the racial homogeneity of the NHS and HPFS cohorts
(490% white), possibly reducing the generalisability of our
findings, although it is unlikely that the underlying biological
pathways of inflammation differ by race.
In conclusion, pre-diagnosis plasma levels of sTNF-RII among
CRC patients are significantly associated with increased overall
mortality. Future studies should continue to explore the role of
inflammatory signalling and methods of reducing inflammation in
patients with colorectal cancer.
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